MRD-guided Prognosis Prediction and Adjuvant Treatment Based on CTC and ctDNA in NSCLC
Recruiting · NCT06198868 · Observational (researchers observe without assigning treatment) · Lead sponsor: Jiangsu Cancer Institute & Hospital
View the official record on ClinicalTrials.gov →Interventions studied
Operable
What this trial is about
This is a prospective cohort study, which aims to evaluate the effectiveness and superiority of a novel minimal residual disease-guided prognosis monitoring and adjuvant treatment in stage IIA-IIIC non-small cell lung cancer.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Written informed consent must be signed before implementing any enrollment-related procedures;
- Age ≥18 years old;
- Patients with histologically or cytologically confirmed stage IIA-IIIC NSCLC (International Association for the Study of Lung Cancer and American Joint Committee on Classification of Cancer, 8th Edition TNM staging)；
- There is no special restriction on the source of genetic test report.
- According to the Response Evaluation Criteria in Solid Tumors (RECIST, version 1.1), there is at least one radiographically measurable lesion.
- Have not received any previous systemic antitumor therapy for advanced diseases.
- No serious abnormalities of hematopoietic function, heart, lung, liver, kidney function and immune system.
- ECOG score: 0-1;
- Expected survival time \> 3 months.
Exclusion criteria
- Received surgical treatment for lung tumors.
- Received neoadjuvant chemotherapy or radiotherapy.
- Received cellular therapy within the last 1 year.
- Treated but uncontrolled diabetes, mellitus, asthma, autoimmune diseases and other chronic diseases.
- Participated in other clinical trials (including research vaccines, drugs, medical devices, etc.) within one month.
Where it is running
1 location listed.
- Jiangsu Cancer Institute & Hospital - Nanjing, Jiangsu, China